Preferred Label : ivacaftor;

MeSH note : a CFTR potentiator; structure in first source;

CISMeF synonym : VX-770; kalydeco;

MeSH synonym : N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide; N-(2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide; 3-quinolinecarboxamide, N-(2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-1,4-dihydro-4-oxo-;

MeSH hyponym : VX 770; VX770 cpd;

Is substance : O;

UNII : 1Y740ILL1Z;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3577036/fr/kalydeco-ivacaftor-mucoviscidose
2025
false
false
false
France
infant
treatment outcome
insurance, health, reimbursement
administration, oral
ivacaftor
evaluation of the transparency committee
cystic fibrosis
ivacaftor

---
https://www.has-sante.fr/jcms/p_3471694/fr/orkambi-lumacaftor/ivacaftor-mucoviscidose
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
lumacaftor, ivacaftor drug combination
drug combinations
ivacaftor
lumacaftor
ivacaftor and lumacaftor
infant
administration, oral
evaluation of the transparency committee
cystic fibrosis

---
https://www.has-sante.fr/jcms/p_3552796/fr/kaftrio-ivacaftor-/-tezacaftor-/-elexacaftor-en-association-avec-kalydeco-ivacaftor-mucoviscidose-enfant-6-ans
2024
false
false
false
France
drug therapy, combination
drug combinations
treatment outcome
insurance, health, reimbursement
elexacaftor, ivacaftor, tezacaftor drug combination
ivacaftor
tezacaftor
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
CFTR delta F508
ivacaftor, tezacaftor and elexacaftor
ivacaftor
administration, oral
evaluation of the transparency committee
elexacaftor
child
cystic fibrosis

---
https://www.has-sante.fr/jcms/p_3517566/fr/kaftrio-ivacaftor/tezacaftor/elexacaftor-en-association-avec-kalydeco-ivacaftor-mucoviscidose-de-2-ans-a-moins-de-6-ans
2024
false
false
false
France
child
treatment outcome
insurance, health, reimbursement
drug combinations
drug therapy, combination
elexacaftor, ivacaftor, tezacaftor drug combination
elexacaftor
tezacaftor
ivacaftor
ivacaftor, tezacaftor and elexacaftor
administration, oral
evaluation of the transparency committee
cystic fibrosis
ivacaftor

---
https://www.has-sante.fr/jcms/p_3478096/fr/kalydeco-ivacaftor-mucoviscidose
2024
false
false
false
France
infant
child
evaluation of the transparency committee
ivacaftor
cystic fibrosis
ivacaftor
Ivacaftor
Cystic Fibrosis
cystic fibrosis
kalydeco
ivacaftor

---
https://ansm.sante.fr/tableau-acces-derogatoire/kaftrio-75-mg-50-mg-100-mg-comprime-pellicule-kalydeco-150-mg-comprime-pellicule
2024
false
false
false
France
French
cystic fibrosis
guidelines for drug use
continuity of patient care
drug therapy, combination
administration, oral
ivacaftor, tezacaftor and elexacaftor
elexacaftor, ivacaftor, tezacaftor drug combination
ivacaftor
tezacaftor
elexacaftor
adult
adolescent
ivacaftor
trikafta
drug combinations
drug information

---
https://www.has-sante.fr/jcms/p_3470456/fr/orkambi-lumacaftor/ivacaftor-mucoviscidose-enfant
2023
false
false
false
France
lumacaftor, ivacaftor drug combination
treatment outcome
insurance, health, reimbursement
ivacaftor
lumacaftor
drug combinations
administration, oral
ivacaftor and lumacaftor
Chloride Channel Agonists
cystic fibrosis
CFTR delta F508
guidelines for drug use
evaluation of the transparency committee
infant
cystic fibrosis

---
https://www.has-sante.fr/jcms/p_3460573/fr/kaftrio-ivacaftor-/-tezacaftor-/-elexacafto-en-association-avec-kalydeco-mucoviscidose-enfant-6-ans
2023
false
false
false
France
insurance, health, reimbursement
treatment outcome
drug therapy, combination
drug combinations
elexacaftor, ivacaftor, tezacaftor drug combination
elexacaftor
ivacaftor
tezacaftor
guidelines for drug use
evaluation of the transparency committee
child
cystic fibrosis

---
https://www.has-sante.fr/jcms/p_3372074/fr/kalydeco-ivacaftor
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
adult
adolescent
child
cystic fibrosis
cystic fibrosis
mutation
infant
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
CFTR gene mutation
ivacaftor
evaluation of the transparency committee
ivacaftor

---
https://www.has-sante.fr/jcms/p_3343179/fr/kaftrio-elexacaftor/-ivacaftor/-tezacaftor-mucoviscidose
2022
false
false
false
France
elexacaftor, ivacaftor, tezacaftor drug combination
ivacaftor
elexacaftor
insurance, health, reimbursement
treatment outcome
administration, oral
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
drug combinations
ivacaftor, tezacaftor and elexacaftor
CFTR delta F508
evaluation of the transparency committee
tezacaftor
cystic fibrosis

---
https://www.has-sante.fr/jcms/p_3343182/fr/kalydeco-ivacaftor-mucoviscidose-6-ans
2022
false
false
false
France
evaluation of the transparency committee
cystic fibrosis
Cystic fibrosis
ivacaftor
cystic fibrosis
traction
indication of
kalydeco
ivacaftor
ivacaftor
indicators
indicators and reagents

---
https://www.has-sante.fr/jcms/p_3327002/fr/kaftrio-ivacaftor-/-tezacaftor-/-elexacafto-en-association-avec-kalydeco-mucoviscidose
https://www.has-sante.fr/jcms/p_3327010/fr/decision-n-2022-0178/dp/sem-du-28-mars-2022-de-la-presidente-de-la-haute-autorite-de-sante-prise-au-nom-du-college-portant-autorisation-d-acces-precoce-de-la-specialite-kaftrio
2022
false
false
false
France
drug therapy, combination
drug combinations
administration, oral
ivacaftor, tezacaftor and elexacaftor
Product containing only elexacaftor and ivacaftor and tezacaftor in oral dose form (medicinal product form)
ivacaftor
tablets
legislation
guidelines for drug use
child
elexacaftor, ivacaftor, tezacaftor drug combination
elexacaftor
ivacaftor
tezacaftor
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
continuity of patient care
forms
professional role
evaluation of the transparency committee
cystic fibrosis

---
https://www.has-sante.fr/jcms/p_3289700/fr/symkevi-tezacaftor/ivacaftor-en-association-avec-kalydeco-ivacaftor-mucoviscidose-enfants-6-ans
2021
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
administration, oral
drug therapy, combination
tezacaftor, ivacaftor drug combination
ivacaftor
cystic fibrosis
cystic fibrosis
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
CFTR delta F508

---
https://www.has-sante.fr/jcms/p_3303740/fr/kaftrio-75-mg/50-mg/100-mg-elexacaftor/-ivacaftor/-tezacaftor
2021
false
false
false
France
CFTR delta F508
elexacaftor
ivacaftor
tezacaftor
drug combinations
treatment outcome
insurance, health, reimbursement
administration, oral
cystic fibrosis
cystic fibrosis
adolescent
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
ivacaftor, tezacaftor and elexacaftor
evaluation of the transparency committee
elexacaftor, ivacaftor, tezacaftor drug combination

---
https://www.has-sante.fr/jcms/p_3302605/fr/kalydeco-150-mg-ivacaftor
2021
false
false
false
France
insurance, health, reimbursement
treatment outcome
drug therapy, combination
elexacaftor, ivacaftor, tezacaftor drug combination
ivacaftor
elexacaftor
tezacaftor
ivacaftor
ivacaftor, tezacaftor and elexacaftor
administration, oral
cystic fibrosis
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
evaluation of the transparency committee

---
https://www.has-sante.fr/jcms/p_3289682/fr/kalydeco-ivacaftor-mucoviscidose-nourrissons-4-6-mois
2021
false
false
false
false
France
treatment outcome
insurance, health, reimbursement
infant
cystic fibrosis
mutation
cystic fibrosis
CFTR Gene
administration, oral
ivacaftor
evaluation of the transparency committee
aminophenols
quinolones
ivacaftor

---
https://www.has-sante.fr/jcms/p_3282752/fr/symkevi-100-mg/150-mg-ivacaftor/-tezacaftor-mucoviscidose-6-ans
2021
false
false
false
France
evaluation of the transparency committee
aminophenols
drug combinations
indoles
quinolones
benzodioxoles
child
adolescent
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
cystic fibrosis
tezacaftor, ivacaftor drug combination
tezacaftor
ivacaftor
ivacaftor and tezacaftor
drug therapy, combination
treatment outcome
insurance, health, reimbursement
administration, oral

---
https://www.ema.europa.eu/en/medicines/human/EPAR/symkevi
2021
false
false
false
Netherlands
French
English
drug approval
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug combinations
tezacaftor, ivacaftor drug combination
tezacaftor
tezacaftor
ivacaftor
ivacaftor
administration, oral
ivacaftor and tezacaftor
Chloride Channel Agonists
Chloride Channel Agonists
cystic fibrosis
drug interactions
pregnancy
breast feeding
child
adolescent
adult
orphan drug production
drug monitoring
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
aged
drug evaluation, preclinical
aminophenols
indoles
quinolones
benzodioxoles
indoles
benzodioxoles
indoles
benzodioxoles
aminophenols
quinolones
aminophenols
quinolones

---
https://www.has-sante.fr/jcms/p_3184439/fr/symkevi-/-kalydeco
2020
false
false
false
France
drug combinations
administration, oral
insurance, health, reimbursement
ivacaftor and tezacaftor
ivacaftor
cystic fibrosis
adolescent
Product containing only ivacaftor and tezacaftor in oral dose form (medicinal product form)
tezacaftor
CFTR delta F508
treatment outcome
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
tezacaftor, ivacaftor drug combination
evaluation of the transparency committee
ivacaftor
aminophenols
quinolones
aminophenols
quinolones
indoles
benzodioxoles

---
https://www.has-sante.fr/jcms/p_3191297/fr/kalydeco
2020
false
false
false
France
ivacaftor
infant
child, preschool
child
treatment outcome
insurance, health, reimbursement
cystic fibrosis
cystic fibrosis transmembrane conductance regulator
mutation
administration, oral
evaluation of the transparency committee
ivacaftor
aminophenols
quinolones
aminophenols
quinolones

---
https://www.has-sante.fr/jcms/p_3220388/fr/kaftrio-/-kalydeco
2020
false
false
false
France
drug combinations
treatment outcome
insurance, health, reimbursement
ivacaftor
Chloride Channel Agonists
tezacaftor
ivacaftor
ivacaftor, tezacaftor and elexacaftor
cystic fibrosis
adolescent
adult
CFTR delta F508
cystic fibrosis transmembrane conductance regulator delta F508
administration, oral
elexacaftor
elexacaftor, ivacaftor, tezacaftor drug combination
evaluation of the transparency committee
aminophenols
quinolones
indoles
benzodioxoles
cystic fibrosis transmembrane conductance regulator
pyrrolidines
pyridines
pyrazoles
drug combinations
quinolines

---
https://www.ema.europa.eu/en/medicines/human/EPAR/kaftrio
2020
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Product containing only elexacaftor and ivacaftor and tezacaftor in oral dose form (medicinal product form)
drug approval
europe
drug combinations
administration, oral
orphan drug production
pyrazoles
pyrazoles
pyridines
pyridines
pyrrolidines
pyrrolidines
ivacaftor
ivacaftor
tezacaftor
tezacaftor
adolescent
adult
cystic fibrosis
drug therapy, combination
cystic fibrosis transmembrane conductance regulator
ivacaftor, tezacaftor and elexacaftor
product surveillance, postmarketing
drug interactions
drug evaluation, preclinical
elexacaftor, ivacaftor, tezacaftor drug combination
elexacaftor, ivacaftor, tezacaftor drug combination
elexacaftor
elexacaftor
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
aminophenols
quinolones
aminophenols
quinolones
indoles
benzodioxoles
indoles
benzodioxoles
quinolines
quinolines

---
https://www.has-sante.fr/jcms/p_3109937/fr/orkambi
2019
false
false
false
France
ivacaftor
lumacaftor
administration, oral
treatment outcome
insurance, health, reimbursement
child
cystic fibrosis
cystic fibrosis transmembrane conductance regulator delta F508
mutation
ivacaftor and lumacaftor
evaluation of the transparency committee
lumacaftor, ivacaftor drug combination
drug combinations
quinolones
benzodioxoles
aminophenols
aminopyridines
cystic fibrosis transmembrane conductance regulator

---
https://www.has-sante.fr/jcms/p_3098921/fr/kalydeco
2019
false
false
false
France
administration, oral
infant
child
cystic fibrosis
ivacaftor
ivacaftor
treatment outcome
insurance, health, reimbursement
evaluation of the transparency committee
aminophenols
quinolones

---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00402
2018
false
false
false
Canada
French
drug information
administration, oral
drug approval
canada
ivacaftor and tezacaftor
drug combinations
tezacaftor
tezacaftor
ivacaftor
ivacaftor
cystic fibrosis
adolescent
adult
cystic fibrosis
cystic fibrosis transmembrane conductance regulator
mutation
treatment outcome
indoles
benzodioxoles
indoles
benzodioxoles
aminophenols
quinolones
aminophenols
quinolones
tezacaftor, ivacaftor drug combination

---
https://www.has-sante.fr/portail/jcms/c_2889886/fr/orkambi
https://www.has-sante.fr/portail/jcms/c_2889886/fr/orkambi-lumacaftor-/-ivacaftor-correcteur-et-potentialisateur-du-gene-cftr
2018
false
false
false
France
French
drug combinations
aminophenols
aminopyridines
aminopyridines
aminophenols
quinolones
quinolones
benzodioxoles
benzodioxoles
adolescent
adult
CFTR gene.p.F508 del
cystic fibrosis transmembrane conductance regulator
cystic fibrosis transmembrane conductance regulator delta F508
cystic fibrosis
ivacaftor
ivacaftor
treatment outcome
ivacaftor and lumacaftor
lumacaftor, ivacaftor drug combination
lumacaftor, ivacaftor drug combination
evaluation of the transparency committee
insurance, health, reimbursement
forced expiratory volume
orphan drug production
guidelines for drug use
lumacaftor
lumacaftor
cystic fibrosis transmembrane conductance regulator

---
http://www.has-sante.fr/portail/jcms/c_2621285/fr/kalydeco-ivacaftor-potentiateur-selectif-de-la-proteine-cftr
2016
false
France
French
mutation
guidelines for drug use
evaluation of the transparency committee
ivacaftor
administration, oral
insurance, health, reimbursement
ivacaftor
ivacaftor
child
cystic fibrosis
orphan drug production
cystic fibrosis transmembrane conductance regulator
CFTR protein, human
cystic fibrosis
treatment outcome
forced expiratory volume
aminophenols
aminophenols
quinolones
quinolones

---
http://www.has-sante.fr/portail/jcms/c_2656337/fr/orkambi
http://www.has-sante.fr/portail/jcms/c_2656337/fr/orkambi-lumacaftor-/-ivacaftor-correcteur-et-potentialisateur-du-gene-cftr
2016
false
false
false
France
French
drug combinations
aminophenols
aminopyridines
aminopyridines
aminophenols
quinolones
quinolones
benzodioxoles
benzodioxoles
adolescent
adult
CFTR gene.p.F508 del
cystic fibrosis transmembrane conductance regulator
cystic fibrosis transmembrane conductance regulator delta F508
cystic fibrosis
ivacaftor
ivacaftor
treatment outcome
ivacaftor and lumacaftor
lumacaftor, ivacaftor drug combination
lumacaftor, ivacaftor drug combination
evaluation of the transparency committee
insurance, health, reimbursement
forced expiratory volume
guidelines for drug use
orphan drug production
lumacaftor
lumacaftor
cystic fibrosis transmembrane conductance regulator
drug combinations
drug combinations

---
https://www.ema.europa.eu/medicines/human/EPAR/Orkambi
2015
false
false
false
United Kingdom
French
English
summary of product characteristics
package leaflet
drug combinations
aminophenols
aminopyridines
aminopyridines
aminophenols
quinolones
quinolones
benzodioxoles
benzodioxoles
continuity of patient care
adolescent
adult
CFTR gene.p.F508 del
cystic fibrosis transmembrane conductance regulator
cystic fibrosis transmembrane conductance regulator delta F508
cystic fibrosis
ivacaftor
ivacaftor
drug evaluation
syndication feed
drug approval
europe
treatment outcome
pregnancy
breast feeding
drug interactions
drug evaluation, preclinical
product surveillance, postmarketing
ivacaftor and lumacaftor
lumacaftor, ivacaftor drug combination
lumacaftor, ivacaftor drug combination
lumacaftor
lumacaftor
cystic fibrosis transmembrane conductance regulator
drug combinations
drug combinations

---
http://www.has-sante.fr/portail/jcms/c_1778225/fr/kalydeco
2014
false
France
French
mutation
evaluation of the transparency committee
ivacaftor
administration, oral
insurance, health, reimbursement
ivacaftor
ivacaftor
child
cystic fibrosis
orphan drug production
cystic fibrosis transmembrane conductance regulator
CFTR protein, human
cystic fibrosis
treatment outcome
clinical trials, phase iii as topic
forced expiratory volume
aminophenols
aminophenols
quinolones
quinolones

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=65036318
2014
summary of product characteristics
dandruff
dandruff
ivacaftor
tablets
aminophenols
ivacaftor
quinolones

---
http://medicalforum.ch/fr/n-actuel/article/ivacaftor-le-premier-medicament-pour-le-traitement-causal-de-la-mucoviscidose.html
https://smf.swisshealthweb.ch/fr/article/doi/fms.2014.02076/
2014
false
false
false
Switzerland
French
journal article
case reports
cystic fibrosis
child
ivacaftor
aminophenols
quinolones
cystic fibrosis
mutation
treatment outcome

---
https://www.ema.europa.eu/medicines/human/EPAR/Kalydeco
2012
false
United Kingdom
English
French
syndication feed
drug evaluation
summary of product characteristics
package leaflet
ivacaftor
ivacaftor
drug approval
treatment outcome
orphan drug production
administration, oral
cystic fibrosis
child
adult
adolescent
cystic fibrosis transmembrane conductance regulator
cystic fibrosis
mutation
drug interactions
pregnancy
breast feeding
fertility
clinical trials, phase iii as topic
drug evaluation, preclinical
aminophenols
aminophenols
quinolones
quinolones
CFTR protein, human

---
http://www.has-sante.fr/portail/jcms/c_1343136/kalydeco
http://www.has-sante.fr/portail/upload/docs/evamed/CT-12472_KALYDECO_Ins_avis%202_CT12474.pdf
2012
false
France
French
evaluation of the transparency committee
ivacaftor
administration, oral
insurance, health, reimbursement
ivacaftor
ivacaftor
child
adolescent
adult
cystic fibrosis
orphan drug production
cystic fibrosis transmembrane conductance regulator
CFTR protein, human
cystic fibrosis
treatment outcome
clinical trials, phase iii as topic
forced expiratory volume
aminophenols
aminophenols
quinolones
quinolones

---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00226
2012
false
Canada
French
English
administration, oral
ivacaftor
ivacaftor
drug approval
canada
summary of product characteristics
ivacaftor
risk assessment
drug evaluation
treatment outcome
child
adolescent
adult
cystic fibrosis
cystic fibrosis
cystic fibrosis transmembrane conductance regulator
CFTR protein, human
mutation
clinical trials as topic
aminophenols
aminophenols
quinolones
quinolones

---
Nous contacter.
26/04/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.